A safety review of long-acting β2-agonists in patients with asthma

Journal of the American Osteopathic Association

Volumn 106, Issue 9, 2006, Pages 562-567

  Rider, Nicholas L ^a   Craig, Timothy J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID DERIVATIVE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TRIAMCINOLONE ACETONIDE;

ADD ON THERAPY; ADRENAL SUPPRESSION; ASTHMA; BONE DENSITY; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPHONIA; GENE TARGETING; GENOTYPE; GLAUCOMA; GROWTH RATE; HUMAN; LUNG FUNCTION; LUNG LAVAGE; MONOTHERAPY; MORTALITY; REVIEW; SIDE EFFECT; THRUSH;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; NEBULIZERS AND VAPORIZERS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 33750687261     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. National Asthma Education and Prevention Program. Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. [published correction in appears in J Allergy Clin Immunol 2003;111:466]. J Allergy Clin Immunol. 2002;110(5 suppl):S141-219.
2. Price AH, Clissold SP. Salbutamol in the 1980s: a reappraisal of its clinical efficacy. Drugs. 1989;38:77-122.
3. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Crockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501-506.
4. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet. 1995;345:41-44.
5. Rabe KF. State of the art in beta2-agonist therapy: a safety review of long-acting agents. Int J Clin Pract. 2003;57:689-697.
6. Salpeter S, Buckley N, Ormiston T, Salpeter E. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904-912. Available at: http://www.annals.org/ cgi/content/full/144/12/904. Accessed August 24, 2006.
7. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; and the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy plus salmeterol [published correction appears in Chest 2006;129:1393]. Chest. 2006;129:15-26. Available at: http://www.chestjournal. org/cgi/content/full/129/1/15 . Accessed August 24, 2006.
8. Labeling changes for drug products that contain salmeterol. FDA Talk Paper. August 14, 2003. Available at http://www.fda.gov/bbs/topics/ANSWERS /2003/ANS01248.html. Accessed September 20, 2006.
9. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327:1420-1425.
10. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
11. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583-2593.
12. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Drazen JM, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001;285:2594-2603.
13. Lee DK, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol. 2003;56:494-500. Available at: http://www. blackwell-synergy.com/doi/full/10.1046/j.1365-2125.2003.01887.x. Accessed August 25, 2006.
14. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29-36.
15. Busse W, Koenig SM, Oppenheimer J, Sahn SA, Yancey SW, Reilly D, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice a day in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice a day. J Allergy Clin Immunol. 2003;111:57-65.
16. Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandstrom T, Lindberg A, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol. 2003;112:72-78.
17. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924-930. Available at: http://ajrccm.ats journals.org/cgi/content/full/158/3/924. Accessed August 25. 2006.
18. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM, et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med. 2004;98:1051-1062.
19. Korosec M, Novak RD, Myers E, Skowronski M, McFadden ER Jr. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med. 1999;107:209-213.
20. van Veen A, Weller FR, Wierenga EA, Jansen HM, Jonkers RE. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther. 2003;16:153-161.
21. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112:469-478.
22. Toogood JH. Side effects of inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:705-713.
23. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377-1383. Available at: http://ajrccm .atsjournals.org/cgi/content/full/165/10/1377. Accessed August 25, 2006.
24. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med. 2001;164:521-535. Available at: http://ajrccm.atsjournals .org/cgi/content/full/164/4/521. Accessed August 25, 2006.
25. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343:1054-1063. Available at: http://content.nejm.org/cgi /content/full/343/15/1054. Accessed August 25, 2006.
26. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-1069. Available at: http://content.nejm.org/cgi/content /abstract/343/15/1064. Accessed August 25, 2006.
27. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocinol Metab Clin North Am. 1998;27:465-483.
28. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003;32:135-157,vii.
29. Toogood JH, Hodsman AB, Fraher LJ, Markov AE, Baskerville JC. Serum osteocalcin and procollagen as markers for the risk of osteoporotic fracture in corticosteroid-treated asthmatic adults. J Allergy Clin Immunol. 1999;104:769-774.
30. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuvsen CI, et al. Genetic susceptibility to asthma - bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med. 1995;333:894-900. Available at: http://content.nejm.org/cgi/content/abstract/333/14/894. Accessed August 25, 2006.
31. Lentes KU, Berrettini WH, Hoehe MR, Chung FZ, Gershon ES. A biallelic DNA polymorphism of the human beta-2-adrenergic receptor detected by Ban I-Adrbr-2. Nucleic Acids Res. 1988;16:2359. Available at: http://www.pubmed central.nih.gov/picrender.fcgi?artid=338245&blobtype=pdf. Accessed August 25, 2006.
32. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993;8:334-339.
33. Lee DK, Currie GP, Hall IP, Lima JJ, Lipworth BJ. The arginine-16 beta2-adrenoreceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol. 2004;57:68-75.
34. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. Effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162:75-80. Available at: http://ajrccm.atsjournals.org/cgi/content /full/162/1/75. Accessed August 25, 2006.
35. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505-1512.
36. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, et al and the National Heart, Lung, and Blood Institute's.Asthma Clinical Research Network. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519-526. Epub December 1, 2005.